Forward
Techno-Blast
Wednesday, March 30, 2016  |  Volume 8 / Number 7  |  A Production of the BioProcessing Journal
Biostat A
ISBioTech 4th Fall Meeting
Career Development
CASSS
5th International
Symposium on HOS
April 11–13, 2016
Long Beach, California USA
CMC Strategy Forum
Europe 2016
May 9–11, 2016
Paris, France
ASGCT
19th Annual Meeting
May 4–7, 2016
Washington, DC USA
PREP
29th International Symposium
July 17–20, 2016
Philadelphia, PA USA
HPLC 2016
44th International Symposium
June 19–24, 2016
San Francisco, CA USA
Cell and Gene Therapy
September 21–22, 2016
Berlin, Germany
Cell and Gene Therapy
ESGCT Annual Meeting
October 18–21, 2016
Florence, Italy
Advertising
Economize by combining Techno-Blast and BioProcessing Journal advertising into one package.

Request a media kit today!
Suggested Reading
Influence of Cell Disruption Methods on the Recovery and Immunogenicity
of a Fusion Protein for a Therapeutic Cancer Vaccine Against HPV
By Miladys Limonta, PhD, Center for Genetic Engineering and Biotechnology (CIGB), et al.
Sponsored Link
The Allegro™ STR single-use bioreactors
The Allegro™ STR single-use bioreactors provide outstanding scalable cell culture performance across the working volume 60 – 1000 L. The cubical design and large bottom-driven impeller give enhanced mixing and aeration for numerous cell culture applications. Supported by an extensive package of characterization data, cell culture data and a complete validation guide, process transfers can be well supported. The intuitive handling and semi-automated installation sequence means that bioreactor installation and inflation can be achieved in less than 30 minutes, with minimal operator manipulation required. The reduced height of the systems allows for easy access from floor level to all bioreactor parts.

Pall Life Sciences
Email: bioreactors@pall.com
www.pall.com/bioreactors
Products & Services
Supporting the Bioimaging Revolution
There is growing demand for public infrastructure to store, share, and link the massive datasets produced using high-resolution imaging techniques. Complementing large-scale, EMBL-led, intergovernmental initiatives such as Euro-BioImaging, the European Bioinformatics Institute (EMBL-EBI) has expanded its EMPIAR data service to accommodate new high-resolution imaging modalities such as Scanning Electron Microscopy (SEM).
EMPIAR, EMBL-EBI’s global public data resource for raw 2D images, provides valuable data for developing new approaches to data processing, interpretation and validation – all essential activities for archiving and quality control. EMPIAR is currently the only way to archive these very large datasets and make them available to other scientists. The average entry is around 700 Gigabytes, and the largest is over 6 Terabytes. The EMPIAR team continues to work on methods to accommodate other imaging modalities. EMPIAR data service
EMPIAR is funded by the Medical Research Council (MRC), Biotechnology and Biomedical Science Research Council (BBSRC), and Wellcome Trust; and is managed by the Protein Data Bank in Europe team at EMBL-EBI. For more information, please visit ebi.ac.uk.
Assays for Testing Biosimilarity of Three Leading Biologics
Sartorius Stedim Biotech (SSB) presents a range of ready-to-use assays for testing Actemra, Stelara, and Lucentis biosimilars. The new assays, launched by SSB’s subsidiary Sartorius Stedim BioOutsource, will allow biopharma manufacturers to generate accurate comparability results rapidly and cost-effectively.
biosimilars
For more information, please visit biooutsource.com.
The new assays available include: Actemra IL-6R Neutralisation Bioassays; an Actemra IL-6R Binding ELISA; Stelara IL-12/IL-23 Binding Assays; a Stelara C1q Binding Assay; a Stelara Neutralisation bioassay; Lucentis VEGF Binding Assays; and a Lucentis VEGF Neutralisation Bioassay. These pre-developed assays complement BioOutsource’s existing portfolio and expands the number of molecules the company can now support to more than nine. The availability of pre-qualified off-the-shelf assays provides biosimilar developers the opportunity to test a wide range of biosimilars utilising assays from just one trusted supplier.
BioOutsource's R&D department is continually adding to its portfolio of assays. Therefore, if an assay is not listed, scientists can contact the firm to discuss its availability, or use the company’s expert services to configure an assay to meet their specific requirements.
Career Development
CIGB
Emerging Targeted Therapies in Cancer and Autoimmunity
April 21–25, 2016
Varadero, Cuba
BEBPA
Host Cell Protein Workshop
May 17–19, 2016
Lisbon, Portugal
ISIA
11th Annual Meeting
May 18–19, 2016
Barcelona, Spain
MSS2016
7th Monolith Summer School and Symposium
May 27–June 1, 2016
Portorož, Slovenia
BPJ Publishing
BioProcessing Journal BioProcessing Journal
Techno-Blast Masthead
A sub-confluent culture of iCell® Endothelial Cells fixed and immunostained for the cell-cell contact protein beta-catenin (green) and tubulin (red).

Courtesy of Cellular Dynamics International, a FUJIFILM company.
Did a colleague forward this to you? Subscribe here. While we'd hate to see you go, you can unsubscribe instantly.

[[tracking_beacon]]